Log In
BCIQ
Print this Print this
 

HM71224

  Manage Alerts
Collapse Summary General Information
Company Hanmi Pharmaceutical Co. Ltd.
DescriptionBruton's tyrosine kinase (Btk) inhibitor
Molecular Target Bruton's tyrosine kinase (Btk)
Mechanism of ActionBruton's tyrosine kinase (Btk) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation
PartnerEli Lilly and Co.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$690.0M

$50.0M

$640.0M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

03/19/2015

$690.0M

$50.0M

$640.0M

Get a free BioCentury trial today